UPDATE: JPMorgan Upgrades Esperion Therapeutics (ESPR) to Neutral Citing 'Achievable Estimates as Outcomes Data Nears'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- Wall St dips as tech declines, Middle East tensions mount
- Oil prices rise after Trump says Iran must pay price
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Has Tesla solved the self-driving puzzle? This analyst thinks so
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Micron to deliver 'another strong quarter', Goldman says
- Needham Starts Hyliion Holdings (HYLN) at Buy
- UK's Ofcom requires tech firms to create crisis response plans
- Supermicro plans $7 billion financing to fund AI server orders
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
May 3, 2022 7:00 AM EDTUnprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation
U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew approximately 109% Y/Y to $13.4 Million in the First Quarter 2022
Retail Prescription Equivalents Grew 56.7% Year over Year
ANN ARBOR, Mich., May 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
"During the first quarter of 2022, our team remained focused on our two primary... More
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
May 3, 2022 7:00 AM EDT Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation
U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew approximately 109% Y/Y to $13.4 Million in the First Quarter 2022
Retail Prescription Equivalents Grew 56.7% Year over Year
ANN ARBOR, Mich., May 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
"During the first quarter of 2022, our team remained... More
Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
May 2, 2022 8:00 AM EDTANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also known as NEXLETOL®, in the American Journal of Cardiology.
The paper, Long-term Safety and Efficacy of Bempedoic Acid in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (From the CLEAR Harmony Open-Label Extension Study), described the results from the 78-week, Phase 3, OLE study that followed the 52-week CLEAR Harmony Phase 3 study. In the CLEAR Harmony study, patients were... More
Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
May 2, 2022 8:00 AM EDTAnalysis of open-label extension data demonstrated that bempedoic acid was generally well tolerated and demonstrated sustained efficacy with up to 2.5 years of continuous treatment
ANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also known as NEXLETOL®, in the American Journal of Cardiology.
The paper, Long-term Safety and Efficacy of Bempedoic Acid in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (From the CLEAR... More
